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Abstract
Background: Thyroid cancer is a rare disease characterized by the subtle appearance of a nodule. Fine-needle
cytology (FNC) is the first diagnostic procedure used to distinguish a benign from a malignant nodule. However,
FNC yields inconclusive results in about 20% of cases. BRAFV600E mutation is the most frequent genetic alteration in
papillary thyroid carcinoma (PTC); its high prevalence makes this oncogene a useful marker to refine inconclusive
FNC results. However, the prevalence of the BRAFV600E mutation depends on detection methods, geographical
factors, and age. The aim of this study is to determine the prevalence of BRAFV600E mutation and its utility as a
diagnostic tool in elderly subjects.
Methods: FNC from 92 PTC patients were subjected to the analysis of BRAF mutation by pyrosequencing and
direct sequencing; age-dependent prevalence was also determined.
Results: BRAF mutation analysis was successful in all FNC specimens. BRAFV600E was documented in 62 (67.4%) and
in 58 (63.0%) PTCs by pyrosequencing and direct sequencing, respectively. BRAFV600E prevalence did not correlate
with patient’s age at diagnosis. Twenty out of 32 PTCs (62.5%) were correctly diagnosed by BRAF mutation analysis
in inconclusive FNC results.
Conclusions: Detection of BRAFV600E in cytology specimens by pyrosequencing is a useful diagnostic adjunctive
tool in the evaluation of thyroid nodules also in elderly subjects.
Introduction
Living in an oxygenated environment has required the
evolution of effective cellular strategies to detect and
detoxify metabolites of molecular oxygen known as
reactive oxygen species. Reactive oxygen species (ROS)
are highly reactive molecules that consist of a number
of diverse chemical species including superoxide anion
(O2-), hydroxyl radical (·OH), and hydrogen peroxide
(H2O2) [1]. Oxidative stress is an important aspect of
cancer, diabetes, neurodegenerative, cardiovascular and
other diseases, and elevated ROS has been implicated in
the mechanism of senescence and aging [2,3]. Oxidant
overproduction occurs in response to several stressors,
including chemicals, drugs, pollutants, high-caloric diets
and exercise [4]. The prevalence of palpable thyroid
nodules in iodine-sufficient regions ranges between 1% -
9% in adults [5]. It is lower in young people and
increases progressively with age. However, the preva-
lence of nodular goiter markedly increases when ultraso-
nography is used. About 75% of individuals over the age
of 80 years have nodules on ultrasound examination.
The majority of thyroid nodules are benign and the inci-
dence of thyroid cancer is low, accounting for about 5%
of nodules [6,7], although it has increased over the last
decades. The increase of incidence is not equally attrib-
uted to all types of thyroid cancer. Papillary thyroid car-
cinoma (PTC) is the most frequent thyroid cancer,
accounting for approximately 85 - 90% of all thyroid
cancers, whereas follicular thyroid carcinoma accounts
for about 10% or less, and poorly differentiated and
undifferentiated or anaplastic carcinomas are very rare
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(approximately 1 - 2%) [8]. The risk of thyroid cancer is
higher in women and people with low iodine intake,
high body mass index and radiation exposure [9-11].
Hashimoto’s Thyroiditis (HT) is a frequent thyroid dis-
order whose prevalence increases with age. PTC is
believed to be more frequent in patients with concurrent
HT. RET rearrangements (RET/PTC) and BRAF point
mutations are genetic alterations occurring in PTC, pro-
posed as tumor markers to refine inconclusive FNC
results. The identification of changes in the expression
of other molecular biomarkers, such as Ca2+-transport-
ing proteins, which have been proposed as an alternative
means for tumor diagnosis [12-19], is still missing.
BRAFV600E is the most frequent mutation in PTC and,
unlike RET/PTC, it has never been detected in benign
thyroid nodules. Its utility as a diagnostic marker
depends upon its prevalence, which varies on the basis
of detection methods and geographical factors. While
RET rearrangements are induced by thyroid exposure to
ionizing radiations, no BRAF mutation inducing factors
have been identified so far. The higher prevalence of
age-related thyroid diseases, such as HT or longer expo-
sure to endocrine disrupters and thyroid toxic agents,
may affect the prevalence of BRAF mutations in elderly
subjects as well as the sensitivity of BRAFV600E as a
tumor marker. The clinical appearance of thyroid cancer
is that of a nodules, some time representing a challen-
ging diagnostic dilemma with thyroid or unusual extra-
thyroidal masses [20,21]. Until serological biomarkers
are available, FNC is the primary diagnostic tool offering
the highest values of sensitivity and specificity [22-27].
Nonetheless, inconclusive results may occur and the
application of molecular techniques to FNC has dramati-
cally increased its sensitivity [25,28-31], including in the
case of HT with diffuse or nodular enlargement [26].
These advantages are enhanced in the case of benign
nodules, which does not require surgical treatment, and
even more in the elderly, where surgery is generally more
burdensome, complex and expensive than in younger
patients [32,33]. Hence, the aims of the present study are
to determine the utility of BRAFV600E mutation detection
as a diagnostic tool to refine inconclusive FNC results in
elderly subjects and whether its sensitivity is age-related.
Material and methods
Patients and clinicopathological data collection
A total of 92 patients with PTC were enrolled in the study
after giving their consent and with the approval from the
institutional review board. Clinicopathological data
included: age at diagnosis, gender, tumor size, and TNM
staging. Tumor volume was calculated according to the
formula of the ellipsoid model: volume (mL) = width ×
length × thickness × □/6. After surgical resection, tissues
were fixed in formalin, embedded in paraffin wax, and
stained with haematoxylin and eosin for microscopy stu-
dies. Standard criteria were employed to classify tumors
and their variants [34]. FNC was performed and classified
according to the British Thyroid Association [35] as
described elsewhere [36,37]. As far as the concomitant
lymphoid infiltrate concerns, its polyclonal, inflammatory
nature was assessed in selected cases by flow cytometry
(FC) and related data were interpreted accordingly [38-41]
in this specific clinical and anatomical setting. Clinico-
pathological data are reported in Table 1.
DNA extraction from cytology samples
Cytology samples were obtained using a syringe with a
22-gauge needle passed three to four times. Material
from the needle was used to prepare a smear for cytol-
ogy, then the needle was washed out with 5 ml of nor-
mal saline into a collection tube, and centrifuged. The
pellet was resuspended into TRI Reagent buffer (Sigma)
and stored at -20 °C for DNA extraction.
Detection of the BRAF mutation
Direct sequencing was performed by BigDye Terminator
method. DNA was amplified by polymerase chain reaction
(PCR) with specific primers, as described previously [42].
Pyrosequencing was performed as described in detail else-
where [42,43]. Briefly, DNA was amplified by PCR, pro-
cessed to obtain single-stranded DNA, hybridized to
sequencing primers, and sequencing-by-synthesis reaction
of the complementary strand was automatically performed
on a PSQ 96MA instrument (Biotage, Uppsala, Sweden).
The cut-off was set at 5%, corresponding to the mean per-
centage of normal tissues plus 2 SD.
Statistics
Results were analyzed by the chi-square of independence
test or the t-test with Prism (Version 3.00 for Windows;
Table 1 Pre-surgical clinicopathological features of PTC
patients with concurrent HT.
Age (years) P
Clinical features < 70 ≥ 70
Number of patients 74 18
Age at diagnosis years, mean, range 79.4, 70-88 50.4, 21-67
Gender (male) 29.8% 33.3% n.s.
Substitutive therapy with L-T4 41.8% 33.3% n.s.
Tumor volume mL, mean, range 1.4, 1.0-22.2 2.5, 1.5-5.5 n.s.
Multinodularity 75% 78% n.s.
Cervical lymphadenopathya 7 2 n.s.
Neck irradiation 0 1
Symptoms of compression 1 0
Fast growthb 0 0
Symptoms of infiltration 0 0
Familiarity for thyroid carcinoma 1 0
a, detected by ultrasonography; b, doubling of the tumor volume in 1 year; n.s.,
not significant
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GraphPad Software, San Diego, CA, USA). The level of
significance was set at P < 0.05.
Results
A total of 92 PTC patients entered the study. Patients
were divided into 2 groups: < 70 years old (No. = 74)
and ≥ 70 years old (No. = 18). The mean age of the 2
groups was 79.4 and 50.4, respectively. Cervical lympha-
denopathy was documented by ultrasonography in 9
subjects; neck irradiation, symptoms of compression and
familiarity for thyroid carcinoma were documented in
1 patient, respectively (Table 1). BRAF mutational analy-
sis was successful in all cytology specimens. BRAFV600E
was documented in 62 patients (67.4%) and in 58
(63.0%) patients by pyrosequencing and direct sequen-
cing, respectively (Table 2). The prevalence of
BRAFV600E mutation in the 2 age groups was similar
(67.6 vs. 66.6 by pyrosequencing in < 70 years vs. ≥70
years, respectively). The mean age of PTC patients
(BRAFV600E positive or negative) was similar (54.4 and
54.3 respectively, P= 0.461). Twenty-four (26.1%) FNCs
yielded inconclusive results (Table 3), 10.9% and 13.4%
were THY3 and THY4, respectively. BRAFV600E muta-
tion was documented in 16 inconclusive FNC results
(66.6%). No significant difference in sensitivity was
documented between young and elderly patients.
Discussion
The clinical utility of molecular testing for inconclusive
FNC results was demonstrated by a number of studies
in the last decade. Among the genetic alterations known
in thyroid cancer, BRAFV600E is the most useful to this
purpose, because of its high sensitivity and its absolute
specificity. However, its sensitivity depends on the
detection method and on its prevalence. cDNA sequen-
cing is the gold standard for the detection of genetic
mutations. However, the sensitivity of these methods is
reduced by the diluting effect of the wild type gene car-
ried by tumor cells and non-tumor cells in the specimen
[23]. This is particularly relevant when other thyroid
diseases are present. Thyroid autoimmunity, and HT in
particular, are frequent in the general female population
and even more frequent in the elderly. These diseases
are characterized by an abundant lymphoplasmacytic
infiltrate of the thyroid and in the late stages by fibrous
atrophy. Hence, the sensitivity of molecular tests applied
to thyroid cytology specimens was hypothesized to be
reduced in elderly subjects [44]. Another possible factor
affecting the sensitivity of BRAFV600E diagnostic tests is
the prevalence of this oncogene in a specific cohort.
Besides the detection methods, racial or geographical
factors are the major determining factors of BRAFV600E
prevalence. This oncogene is much more frequent in the
Korean population than in any other, being detected in
about 90% of PTCs. Its high prevalence can be the result
of a particular genetic imprinting or the effect of food or
environmental factors. Iodine diet content and goitrogen
factors, the exposure to ionizing radiations, endocrine
disrupters and thyroid toxic agents can be relevant in
the development of thyroid cancer. A low iodine diet
has been associated with a higher prevalence of thyroid
cancer, with a higher papillary/follicular thyroid ratio
[45]. Also, the exposure to ionizing radiations is a risk
factor for the development of thyroid cancer. The
genetic rearrangement of the proto-oncogene RET gen-
erates chimeric proteins (RET/PTC) with demonstrated
carcinogenetic properties. RET rearrangements, and
RET/PTC3 in particular, are induced by the exposure to
ionizing radiations, so that their prevalence is increased
in the exposed populations [46,47]. Time of exposition
to interfering agents is crucial for carcinogenesis, so that
the risk of thyroid cancer development is age-dependent.
Studies on population of different geographic areas
showed the reduction of RET/PTC in thyroid tumors in
older subjects [48,49]. Although BRAFV600E has been
extensively investigated, evidence on the etiology of this
oncogene is lacking. Study results indicate that the preva-
lence of BRAFV600E does not change in elderly subjects
and that it can be used as a PTC marker in inconclusive
FNC results. The sensitivity of the Big Dye terminator
method is low since it is based on an automated or sub-
jective evaluation of a chromatogram. For this reason,
mutations detected in less than 20% of PCR products
yield ambiguous or false negative results [50]. Accord-
ingly, BRAFV600E detection in this study was higher by
pyrosequencing analysis than by direct sequencing, and
PTC was correctly diagnosed in 66.6% of FNC inconclu-
sive results by means of this method.
Table 2 Prevalence of BRAFV600E mutation in 92 PTCs.
Age (years) Direct Sequencing Pyrosequencing
<70 11 (61.1) 12 (66.6)
≥70 47 (63.5) 50 (67.6)
P n.s. n.s.
Number of positive samples (and percentages).
n.s., not significant
Table 3 FNC results and detection of BRAFV600E mutation
by pyrosequencing.
FNC Age, > 70 years Age, ≥ 70 years
TYH total BRAFV600E total BRAFV600E
3 8 6 (75.0) 2 1 (50.0)
4 11 7 (63.6) 3 2 (66.6)
5 55 37 (67.2) 13 9 (69.2)
Number of positive samples (and percentages).
TYH 3, indeterminate; TYH4, suspicious for malignancy; TYH5, malignant
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Conclusions
The prevalence of BRAFV600E mutation in PTCs of
elderly subjects is similar to that of younger subjects.
The detection of BRAFV600E mutation in cytology speci-
mens by pyrosequencing is a useful diagnostic adjunc-
tive tool in the evaluation of thyroid nodules also in
elderly subjects.
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